USPTO serial 79191235
LOPRO90
Reviewed by CopyMark Law Group
Reg. 5582622Status 709
- Filing date
- Status date
- Registration date
- Oct 16, 2018
- Examiner
- JACKSON, SHA-KARA ELOUISE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LOPRO90?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey H. Greger
Jeffrey H. Greger Roberts Mlotkowski Safran & Cole P.C.7918 Jones Branch Drive, Suite 500McLean, VA 22102UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Surgical apparatus and instruments; medical apparatus and instruments for use in cardiovascular procedures; prosthetic vascular grafts; prosthetic endovascular grafts; stents, patches for repair and reconstruction of internal tissue, namely, cardiovascular patches, pericardial patches, carotid patches, and vascular prostheses; vascular prostheses; surgical implants comprising prosthetic materials; suture materials namely, cardiac valves for surgical prostheses, stents, prosthetic vascular grafts, vascular prostheses, prosthetic vascular grafts, prosthetic endovascular grafts, and catheters; artificial implants, namely, patches for repair and/or reconstruction of internal tissue; implantable medical systems consisting of stent grafts and stent graft delivery systems; implantable medical devices consisting of artificial materials; synthetic vascular grafts; synthetic endovascular grafts; synthetic surgical graft materials, namely, vascular prostheses for the treatment of aneurysmal or occlusive arterial disease ; medical systems, namely, cardiac valves for surgical prostheses, stents, prosthetic vascular grafts, vascular prostheses, prosthetic vascular grafts, prosthetic endovascular grafts, and catheters; medical devices, namely, implantable medical devices, namely, implants consisting of artificial materials, synthetic vascular prostheses, artificial vascular grafts, and synthetic heart valve conduits; artificial vascular grafts; medical systems and medical devices for use in endovascular procedures; thoracic stents; thoracic stent grafts; stent grafts; stent graft systems; stent graft devices; stent graft systems and devices comprising more than one component; stent graft systems and devices comprising components of more than one stent graft; stent graft systems and devices comprising components of more than one type of stent graft; thoracic stent graft systems, consisting of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; thoracic stent graft devices; delivery systems for stent graft systems and stent graft devices; aneurysm repair systems consisting of catheter delivered stent grafts, medical instruments for intraluminal emplacement of stents or stent systems or of synthetic stent grafts, namely, stent delivery systems or stent graft delivery systems or synthetic stent graft delivery systems; aneurysm repair devices; cardiac valves for surgical prostheses; cardiac valve replacement systems consisting of artificial cardiac valves; artificial heart valves; artificial heart valve conduits; synthetic cardiac patches; synthetic vascular patches; synthetic cardiovascular patches; synthetic thoracic patches; synthetic tissue patches; parts and fittings for all of the aforementioned goods; all the foregoing excluding electrosurgical probes, electrodes and power supplies for electrodes, carrying cases and bags fitted for medical instruments for use by doctors, medical bags adapted for medical, surgical and veterinary instruments and cases fitted for medical instruments for use by doctors | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 27, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 4, 2026 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 4, 2026 | INPC | INVALIDATION PROCESSED | — |
| Jan 2, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 2, 2025 | C71T | CANCELLED SECTION 71 | — |
| Oct 16, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 15, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 27, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 27, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 16, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 16, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 12, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 31, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 31, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 11, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 11, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 11, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 24, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 1, 2018 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 31, 2018 | ALIE | ASSIGNED TO LIE | — |
| Mar 2, 2018 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 14, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 14, 2018 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 13, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 13, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 13, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 23, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 23, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 16, 2017 | ALIE | ASSIGNED TO LIE | — |
| Oct 3, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 24, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 24, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 24, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 9, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 8, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 8, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 25, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 10, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 10, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 4, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 3, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 27, 2016 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Oct 7, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 6, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 3, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 13, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 9, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 8, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |